Silence Therapeutics rose after Cantor Fitzgerald initiated coverage with an Overweight rating and a positive view on its lead drug candidate. The note is a supportive analyst initiation rather than a fundamental update, but it can still improve sentiment around the stock. The article does not disclose price targets or clinical/data changes.
Silence Therapeutics rose after Cantor Fitzgerald initiated coverage with an Overweight rating and a positive view on its lead drug candidate. The note is a supportive analyst initiation rather than a fundamental update, but it can still improve sentiment around the stock. The article does not disclose price targets or clinical/data changes.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.40
Ticker Sentiment
